New strategies for the management of no-reflow after primary percutaneous coronary intervention

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 5, 2011, Pages 615-630

  Niccoli, Giampaolo ^a   Cosentino, Nicola ^a   Spaziani, Cristina ^a   Minelli, Silvia ^a   Fracassi, Francesco ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

myocardial no reflow; prevention; primary percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ADENOSINE; ATRIAL NATRIURETIC FACTOR; CARIPORIDE; CARVEDILOL; CYCLOSPORIN; ENIPORIDE; ERYTHROPOIETIN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NICORANDIL; NITRATE; NITROPRUSSIDE SODIUM; PEXELIZUMAB; SIMVASTATIN; VERAPAMIL;

AORTA BALLOON; ARTIFICIAL EMBOLISM; BLOOD CLOT LYSIS; DIABETIC PATIENT; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HEART VENTRICLE FUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC PRECONDITIONING; LEUKOCYTE ACTIVATION; MICROCIRCULATION; NO REFLOW PHENOMENON; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THROMBECTOMY; THROMBUS ASPIRATION; TREATMENT DURATION;

ANIMALS; CORONARY VESSELS; EMBOLISM; ENDOVASCULAR PROCEDURES; HEART CATHETERIZATION; HUMANS; MICROCIRCULATION; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL REVASCULARIZATION; NO-REFLOW PHENOMENON;

EID: 79959305701     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.49     Document Type: Review

References (106)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361, 13-20 (2003) (Pubitemid 36050955)
2. Kloner RA, Ganote CE, Jennings RB. The 'no reflow' phenomenon after temporary occlusion in the dog. J. Clin. Invest. 54, 1496-1508 (1974)
3. Summers WK, Jamison RL. The no reflow phenomenon in renal ischemia. Lab. Invest. 25, 635-643 (1971)
4. Majno GA, Chaing J, Wright RL. No reflow after cerebral ischemia. Lancet 2, 569-570 (1967)
5. Willms-Kretschmer, K., Majno G. Ischemia of the skin. Electron microscopic study of vascular injury. Am. J. Pathol. 54, 327-343 (1969)
6. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter. Cardiovasc. Interv. 72, 950-957 (2008)
7. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur. Heart J. 22, 729-739 (2001) (Pubitemid 32625230)
8. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E; TIMI Study Group. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 105, 1909-1913 (2002) (Pubitemid 34437617)
9. McLaughlin MG, Stone GW, Aymong E et al. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. J. Am. Coll. Cardiol. 44, 1215-1223 (2004) (Pubitemid 39208876)
10. Bolognese L, Carrabba N, Parodi G et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 109, 1121-1126 (2004)
11. Galiuto L, Garramone B, Scarà A et al.; AMICI Investigators. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. J. Am. Coll. Cardiol. 51, 552-559 (2008)
12. Soraja P, Gersh BJ, Costantini C et al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. Eur. Heart J. 26, 667-674 (2005) (Pubitemid 40516878)
13. Brosh D, Assali AR, Mager A et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am. J. Cardiol. 99, 442-445 (2007) (Pubitemid 46223482)
14. Henriques JP, Zijlstra F, van't Hof AW et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 107, 2115-2119 (2003) (Pubitemid 36532193)
15. Ndrepepa G, Tiroch K, Fusaro M et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 55, 2383-2389 (2010)
16. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J. Am. Coll. Cardiol. 54, 281-292 (2009)
17. Niccoli G, Kharbanda RK, Crea F, Banning AP. No-reflow: again prevention is better than treatment. Eur. Heart J. 31, 2449-2445 (2010).
18. Tranum-Jensen J, Janse MJ, Fiolet WT, Krieger WJ, D'Alnoncourt CN, Durrer D. Tissue osmolality, cell swelling, and reperfusion in acute regional myocardial ischemia in the isolated porcine. Circ. Res. 49, 364-381 (1981) (Pubitemid 11053297)
19. Turschner O, D'hooge J, Dommke C et al. The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. Eur. Heart J. 25, 794-803 (2004) (Pubitemid 38647940)
20. Iwakura K, Ito H, Kawano S et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J. Am. Coll. Cardiol. 38, 472-477 (2001) (Pubitemid 32721776)
21. Heusch G, Kleinbongard P, Böse D et al. Coronary microembolization: from bedside to bench and back to bedside. Circulation 120, 1822-1836 (2009)
22. Skyschally A, Leineweber K, Gres P, Haude M, Erbel R, Heusch G. Coronary microembolization. Basic Res. Cardiol. 101, 373-382 (2006) (Pubitemid 44275870)
23. Hori M, Inoue M, Kitakaze M et al. Role of adenosine in hyperemic response of coronary blood flow in microembolization. Am. J. Physiol. 250, H509-H518 (1986)
24. Skyschally A, Schulz R, Erbel R, Heusch G. Reduced coronary and inotropic reserves with coronary microembolization. Am. J. Physiol. Heart Circ. Physiol. 282, H611-H614 (2002) (Pubitemid 34654985)
25. Ross J Jr. Myocardial perfusion-contraction matching. Circulation 83, 1076-1083 (1991)
26. Dorge H, Neumann T, Behrends M et al. Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation. Am. J. Physiol. Heart Circ. Physiol. 279, H2587-H2592 (2000) (Pubitemid 32005842)
27. Yip HK, Chen MC, Chang HW et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest 122, 1322-1332 (2002)
28. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch. Pathol. 70, 68-78 (1960)
29. Zalewski J, Undas A, Godlewski J, Stepien E, Zmudka K. No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis. Arterioscler. Thromb. Vasc. Biol. 2258-2265 (2007) (Pubitemid 350287258)
30. Collet JP, Montalescot G. The acute reperfusion management of STEMI in patients with impaired glucose tolerance and Type 2 diabetes. Diabetes Vasc. Dis. Res. 2, 136-143 (2005) (Pubitemid 41695172)
31. Iwakura K, Ito H, Ikushima M et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 41, 1-7 (2003) (Pubitemid 36044395)
32. Golino P, Maroko PR, Carew TE. The effect of acute hypercholesterolemia on myocardial infarct size and the no-reflow phenomenon during coronary occlusion-reperfusion. Circulation 75, 292-298 (1987) (Pubitemid 17234570)
33. Galiuto L, Lombardo A, Maseri A et al. Temporal evolution and functional outcome of no-reflow: sustained and spontaneously reversible patterns following successful coronary recanalization. Heart 89, 731-737 (2003) (Pubitemid 36760629)
34. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 105, 656-662 (2002) (Pubitemid 34123444)
35. Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. N. Engl. J. Med. 357, 1631-1638 (2007)
36. Montalescot G, Ongen Z, Guindy R et al.; RIVIERA Investigators. Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study. Int. J. Cardiol. 129(3), 379-387 (2007)
37. Zhao JL, Yang YJ, You SJ et al. Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Coron. Artery Dis. 17, 463-469 (2006)
38. Karmazyn M, Gan XT, Humphreys RA, Yoshida H, Kusumoto K. The myocardial Na+-H+ exchange: structure, regulation, and its role in heart disease. Circ. Res. 85, 777-786 (1999) (Pubitemid 29504152)
39. Théroux P, Chaitman BR, Danchin N et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial. Circulation 102, 3032-3038 (2000)
40. Zeymer U, Suryapranata H, Monassier JP et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction: results of the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI) trial. J. Am. Coll. Cardiol. 38, 1644-1650 (2001) (Pubitemid 33065449)
41. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol. Rev. 83, 1113-1151 (2003) (Pubitemid 37222269)
42. Peart JN, Headrick JP. Clinical cardioprotection and the value of conditioning responses. Am. J. Physiol. Heart Circ. Physiol. 296, H1705-H1720 (2009)
43. Jerome SN, Akimitsu T, Gute DC, Korthuis RJ. Ischemic preconditioning attenuates capillary no-reflow induced by prolonged ischemia and reperfusion. Am. J. Physiol. 268, H2063-H2067 (1995)
44. Malmberg K, Rydén L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J. Am. Coll. Cardiol. 26, 56-65 (1995)
45. Malmberg K, Rydén L, Wedel H et al.; DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur. Heart J. 26, 650-661 (2005) (Pubitemid 40516876)
46. Mellbin LG, Malmberg K, Norhammar A et al.; DIGAMI 2 Investigators. The impact of glucose-lowering treatment on long-term prognosis in patients with Type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur. Heart J. 29, 166-176 (2008)
47. Lefer DJ. Statins as potent anti-inflammatory drugs. Circulation 106, 2041-2042 (2002)
48. Zhao J-L, Yang Y-J, Cui C-J, You S-J, Gao R-L. Pretreatment with simvastatin reduced myocardial no-reflow by opening mitochondrial KATP channel. Br. J. Pharmacol. 149, 243-249 (2006) (Pubitemid 44453424)
49. Iwakura K, Ito H, Kawano S et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur. Heart J. 27, 534-539 (2006).
50. Ambrosio G, Del Pinto M, Tritto I et al. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patient in the Global Registry of Acute Coronary Events. Eur. Heart J. 31, 430-438 (2010)
51. Kloner RA, Shook T, Przyklenk K et al.; for the TIMI 4 Investigators. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 91, 37-47 (1995)
52. Andreotti F, Pasceri V, Hackett DR, Davies GJ, Haider AW, Maseri A. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N. Engl. J. Med. 334, 7-12 (1996) (Pubitemid 26012497)
53. Karila-Cohen D, Czitrom D, Brochet E et al. Decreased no-reflow in patients with anterior myocardial infarction and pre-infarction angina. Eur. Heart J. 20, 1724-1730 (1999)
54. Przyklenk K, Bauer B, Ovize M et al. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 87, 893-899 (1993) (Pubitemid 23070821)
55. Pell TJ, Baxter GF, Yellon DM et al. Renal ischemia preconditions myocardium: role of adenosine receptors and ATP-sensitive potassium channels. Am. J. Physiol. 275, H1542-H1547 (1998)
56. Gho BC, Schoemaker RG, Van Den Doel MA et al. Myocardial protection by brief ischemia in non-cardiac tissue. Circulation 94, 2193-2200 (1996) (Pubitemid 26360513)
57. Bøtker HE, Kharbanda R, Schmidt MR et al. Remote ischemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375, 727-734 (2010)
58. Burzotta F, Trani C, Romagnoli E et al. Manual thrombus-aspiration improves myocardial reperfusion: the Randomized Evaluation of The Effect of Mechanical Reduction of Distal Embolization by Thrombus-Aspiration in Primary and Rescue Angioplasty (REMEDIA) trial. J. Am. Coll. Cardiol. 46, 371-376 (2005) (Pubitemid 40966871)
59. Galiuto L, Garramone B, Burzotta F et al. REMEDIA Investigators. Thrombus aspiration reduces microvascular obstruction after primary coronary intervention: a myocardial contrast echocardiography substudy of the REMEDIA trial. J. Am. Coll. Cardiol. 48, 1355-1360 (2006) (Pubitemid 44436805)
60. Burzotta F, Testa L, Giannico F et al. Adjunctive devices in primary or rescue PCI: a meta-analysis of randomized trials. Int. J. Cardiol. 123, 313-321 (2008) (Pubitemid 350297454)
61. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur. Heart J. 29(24), 2989-3001 (2008)
62. Svilaas T, Vlaar PJ, van der Horst IC et al. Thrombus aspiration during primary percutaneous coronary intervention. N. Engl. J. Med. 358, 557-567 (2008) (Pubitemid 351214283)
63. De Luca G, Dudek D, Sardella G, Marino P, Chevalier B, Zijlstra F. Adjunctive Manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur. Heart J. 29, 3002-3010 (2008)
64. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J. Am. Coll. Cardiol. 44, 1103-1110 (2004) (Pubitemid 39165147)
65. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 204, 334-341 (2009)
66. Hansen PR, Thibault H, Abdulla J. Postconditioning during primary percutaneous coronary intervention: a review and meta-analysis. Int. J. Cardiol. 144, 22-25 (2010)
67. Lønborg J, Kelbaek H, Vejlstrup N et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ. Cardiovasc. Interv. 3, 34-41 (2010)
68. Sörensson P, Saleh N, Bouvier F et al. Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart 96, 1710-1715 (2010)
69. Lønborg J, Holmvang L, Kelbak H et al. ST-segment resolution and clinical outcome with ischemic postconditioning and comparison to magnetic resonance. Am. Heart J. 160, 1085-1091 (2010)
70. Glazier JJ. Attenuation of reperfusion microvascular ischemia by aqueous oxygen: experimental and clinical observations. Am. Heart J. 149, 580-584 (2005)
71. Cameron AJV, Hutton L, Kenmure ACF, Murdoch WR. Haemodynamic and metabolic effects of hyperbaric oxygen in myocardial infarction. Lancet 2, 833-887 (1966)
72. Sterling DL, Thornton JD, Swafford A et al. Hyperbaric oxygen limits infarct size in ischemic rabbit myocardium in vivo. Circulation 88, 1931-1936 (1993) (Pubitemid 23296941)
73. Trabattoni D, Bartorelli AL, Fabbiocchi F et al. Hyperoxemic perfusion of the left anterior descending coronary artery after primary angioplasty in anterior ST-elevation myocardial infarction. Catheter. Cardiovasc. Interv. 67, 859-865 (2006) (Pubitemid 43837068)
74. O'Neill WW, Martin JL, Dixon SR et al. Acute myocardial infarction with hyperoxemic therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. J. Am. Coll. Cardiol. 50(5), 397-405 (2007) (Pubitemid 47088128)
75. Petronio AS, De Carlo M, Ciabatti N et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am. Heart J. 150, 1015 (2005)
76. Thiele H, Schindler K, Friedenberger J et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction trial. Circulation 118, 49-57 (2008)
77. Gu YL, Kampinga MA, Wieringa WG et al. Intracoronary versus intravenous administration of abciximab in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the Comparison of Intracoronary Versus Intravenous Abciximab Administration During Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) Trial. Circulation 122(25), 2709-2717 (2010)
78. Danzi GB, Sesana M, Capuano C, Mauri L, Berra Centurini P, Baglini R. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am. J. Cardiol. 94, 35-39 (2004) (Pubitemid 38813450)
79. Claeys MJ, Bosmans J, De Ceuninck M et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am. J. Cardiol. 94, 9-13 (2004) (Pubitemid 38813445)
80. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 101, 2154-2159 (2010)
81. Stoel MG, Marques KM, de Cock CC, Bronzwaer JG, von Birgelen C, Zijlstra F. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study. Catheter. Cardiovasc. Interv. 71, 283-289 (2008) (Pubitemid 351428141)
82. Mahaffey KW, Puma JA, Barbagelata NA et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J. Am. Coll. Cardiol. 34, 1711-1720 (1999)
83. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW; AMISTAD-II Investigators. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II)J. Am. Coll. Cardiol. 45, 1775-1780 (2005) (Pubitemid 40779856)
84. Micari A, Belcick TA, Balcells EA et al. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am. J. Cardiol. 96, 1410-1415 (2005) (Pubitemid 41566624)
85. Amit G, Cafri C, Yaroslavtsev S, Fuchs S et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am. Heart J. 152, 887.e9-e14 (2006)
86. Shinozaki N, Ichinose H, Yahikozawa K, Shimada H, Hoshino K. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction. Int. Heart J. 48, 423-433 (2007) (Pubitemid 47455793)
87. Ishii H, Ichimiya S, Kanashiro M et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 112, 1284-1288 (2005) (Pubitemid 41266722)
88. Ito H, Taniyama Y, Iwakura K et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J. Am. Coll. Cardiol. 33, 654-660 (1999)
89. Ono H, Osanai T, Ishizaka H et al. Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation. Am. Heart J. 148, E15 (2004)
90. Hayashi M, Tsutamoto T, Wada A et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J. Am. Coll. Cardiol. 37, 1820-1826 (2001) (Pubitemid 32499965)
91. Taniyama Y, Ito H, Iwakura K et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 30, 1193-1199 (1997) (Pubitemid 27501434)
92. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter. Cardiovasc. Interv. 57, 444-451 (2002) (Pubitemid 35424121)
93. Piot C, Croisille P, Staat P et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med. 359, 473-481 (2008)
94. Armstrong PW, Granger CB, Adams PX et al.; APEX AMI Investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 297, 43-51 (2007) (Pubitemid 46041725)
95. Atar D, Petzelbauer P, Schwitter J et al.; F.I.R.E. Investigators. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J. Am. Coll. Cardiol. 53, 720-729 (2009)
96. Kitakaze M, Asakura M, Kim J et al.; J-WIND Investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370, 1483-1493 (2007) (Pubitemid 47625560)
97. Namiuchi S, Kagaya Y, Ohta J et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J. Am. Coll. Cardiol. 45, 1406-1412 (2005) (Pubitemid 40615610)
98. Ehrenreich H, Weissenborn K, Prange H et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40, e647-e656 (2009)
99. Ferrario M, Arbustini E, Massa M et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int. J. Cardiol. 147(1),124-131 (2009)
100. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am. J. Cardiol. 104, 1035-1040 (2009)
101. Voors AA, Belonje AM, Zijlstra F et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur. Heart J. 31, 2593-2600 (2010)
102. Brines M, Cerami A. Discovering erythropoietin's extrahematopoietic functions: biology and clinical promise. Kidney Int. 70, 246-250 (2006) (Pubitemid 44086573)
103. Amado LC, Kraitchman DL, Gerber BL et al. Reduction of 'no-reflow' phenomenon by intra-aortic balloon counterpulsation in a randomized magnetic resonance imaging experimental study. J. Am. Coll. Cardiol. 43, 1291-1298 (2004). (Pubitemid 38452609)
104. Maekawa K, Kawamoto K, Fuke S et al. Effects of intraaortic balloon pumping on the angiographic no-reflow phenomenon after percutaneous coronary intervention in patients with anterior myocardial infarction. Circ. J. 70, 37-43 (2006) (Pubitemid 43021232)
105. Sjauw KD, Engstrom AE, Vis MM et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur. Heart J. 30, 459-468 (2009)
106. Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 29, 2909-2945 (2008).